

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
27 May 2022 (27.05.2022)



(10) International Publication Number
WO 2022/109106 A1

(51) International Patent Classification:

A61K 31/4433 (2006.01) A61P 35/00 (2006.01)
A61K 31/4166 (2006.01) A61P 35/04 (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:

PCT/US2021/059847

(22) International Filing Date:

18 November 2021 (18.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/115,165 18 November 2020 (18.11.2020) US

(71) Applicant: **CONSTELLATION PHARMACEUTICALS, INC** [US/US]; 215 First Street, Suite 200, Cambridge, MA 02142 (US).

(72) Inventors: **BRADLEY, William, D.**; 28 Elm Street, Winchester, MA 01890 (US). **CUI, Jike**; 78 Maple Street, Belmont, MA 02478 (US). **SUN, Kaiming**; 24 Charles St., Belmont, MA 02478 (US). **TROJER, Patrick**; 57 Longwood Road, Reading, MA 01867 (US). **WANG, Jing**; 118 Burlington Street, Lexington, MA 02420 (US). **WU, Rentian**; 45 Allen Road, Winchester, MA 01890 (US).

(74) Agent: **DAVIS, Steven, G.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: EZH2 INHIBITION THERAPIES FOR THE TREATMENT OF ANDROGEN RECEPTOR MUTATED PROSTATE CANCERS

(57) Abstract: Provided herein are methods of treating prostate cancer having at least one pathogenic AR mutation using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharmaceutically acceptable salt thereof, alone or in combination with a therapeutically effective amount of an androgen receptor signaling inhibitor (ARSI) such as enzalutamide.

WO 2022/109106 A1